Toward a cocaine vaccine to help addicts kick the habit
In their decades-long search for vaccines against drugs of abuse, scientists have hit upon a new approach to annul cocaine’s addictive buzz. They report in the ACS journal Molecular Pharmaceutics that their strategy, which they tested on mice, harnesses a bacterial protein to trigger an immune system attack on the drug if it enters the body. This response could dull cocaine’s psychotropic effects and potentially help users of the drug kick the habit.
Kim D. Janda and colleagues note that according to the 2011 National Survey on Drug Use and Health, an estimated 1.4 million people in the U.S. took cocaine. A number of therapies are available to help drug abusers quit. But addiction is extremely tough to beat. So some scientists are working on vaccines to neutralize the high-inducing effects of recreational drugs. Although vaccines are normally associated with fighting bacterial or viral infections, they can also be designed to recruit the body’s immune system to recognize non-microbial substances such as drugs. None so far are widely effective, so Janda’s team set out to try a new approach.
The researchers took a safe bacterial protein called flagellin that has already been incorporated in other vaccines and modified it to boost the immune response to cocaine. They tested the compound in mice and found that it worked better than a vaccine candidate they’d developed previously. The strategy, the researchers conclude, opens up a new avenue for designing vaccines against drugs of abuse.
The authors acknowledge funding from the Skaggs Institute for Chemical Biology, the National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 161,000 members, ACS is the world’s largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.